长期、稳定、安全的血糖达标——记诺华第四届糖尿病高层专家研讨会

[1] Indication for nateglinide in type2diabetes mellitus. Kishikawa H,Okada Y,Kanda K,et al. Journal of UOEH . 2005

[2] Treatment of patients over64years of age with type2diabetes experience from nateglinide pooled database retrospective analysis. Del Prato S,Heine RJ,Keilson L,et al. Diabetes Care . 2003

[3] Addition of nateglimide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and unproves overall glycemic control. Fonseca V,Grunberger G,Gupta S,et al. Diabetes Care . 2003

[4] Contributions of fasting and poslprandial plasma glucose increments to the overall diurnal hyperglycemia of type2diabetic patients. Monnier L,Lapinski H,Colette C. Diabetes Care . 2003

[5] Impairment of early insulin response after glucose load,rather than insulin resistance,is responsible for postprandial hyperglycemia seen in obese type2diabetes:assessment using nateglinide,a newinsulin secretagogue. Uchino H,Niwa M,Shimizu T,et al. Endocrine Journal . 2000

[6] Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatmentnaive patients with type2diabetes. Horton E,Foley JE,Shen SG,et al. Current Medical Research and Opinion . 2004

[1] Indication for nateglinide in type2diabetes mellitus. Kishikawa H,Okada Y,Kanda K,et al. Journal of UOEH . 2005

[2] Treatment of patients over64years of age with type2diabetes experience from nateglinide pooled database retrospective analysis. Del Prato S,Heine RJ,Keilson L,et al. Diabetes Care . 2003

[3] Addition of nateglimide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and unproves overall glycemic control. Fonseca V,Grunberger G,Gupta S,et al. Diabetes Care . 2003

[4] Contributions of fasting and poslprandial plasma glucose increments to the overall diurnal hyperglycemia of type2diabetic patients. Monnier L,Lapinski H,Colette C. Diabetes Care . 2003

[5] Impairment of early insulin response after glucose load,rather than insulin resistance,is responsible for postprandial hyperglycemia seen in obese type2diabetes:assessment using nateglinide,a newinsulin secretagogue. Uchino H,Niwa M,Shimizu T,et al. Endocrine Journal . 2000

[6] Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatmentnaive patients with type2diabetes. Horton E,Foley JE,Shen SG,et al. Current Medical Research and Opinion . 2004